To determine whether C5aR deficiency conferred better tumor control depending on enhanced T cell responses, we depleted CD8+ T cells or CD4+ T cells in C5aR−/− tumor-bearing mice with anti-CD8 or anti-CD4 antibodies. This evidence concerns the gene CD8A and neoplasm.